Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study

Acarbose and repaglinide are widely used either by themselves or in combination with other medications. However, their efficacy in diabetes control has not been compared when used in combination with metformin. The present study aimed to compare their effects on glycemic variability (GV) control whe...

Full description

Saved in:
Bibliographic Details
Published in:PeerJ (San Francisco, CA) CA), 2020-10, Vol.8, p.e9905-e9905, Article e9905
Main Authors: Du, Guoli, Xie, Wanrun, Su, Yinxia, Ma, Yao, Gao, Xiaoming, Jiang, Sheng, Liang, Huazheng
Format: Article
Language:English
Subjects:
Acarbose
Blood glucose
Blood pressure
Body mass index
Care and treatment
Cholesterol
Cohort analysis
Comparative analysis
Diabetes
Diabetes and Endocrinology
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes therapy
Drugs and Devices
Evidence Based Medicine
Glucose
Glucose variability
Hospitals
Hyperglycemia
Hypoglycemia
Lipoproteins
Medical records
Medical research
Metformin
Mortality
Repaglinide
Statistical analysis
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acarbose and repaglinide are widely used either by themselves or in combination with other medications. However, their efficacy in diabetes control has not been compared when used in combination with metformin. The present study aimed to compare their effects on glycemic variability (GV) control when taken with metformin for type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. In this retrospective cohort study, T2DM patients who were treated with either acarbose-metformin or repaglinide-metformin combination were recruited. Either acarbose 100 mg or repaglinide 2 mg triple daily was taken for the subsequent 12 weeks in combination with metformin. Demographic data, biochemical data and 7-point glycemic self-monitoring conducted with capillary blood (SMBG) data were reviewed after one week and 12 weeks. The primary outcome including glucose control and changes in GV as well as other factors affecting GV and the incidence of hypoglycemia were also analyzed. Of the 305 T2DM patients enrolled, data from 273 subjects, 136 in the acarbose-metformin group (M+A) and 137 in the repaglinide-metformin group (M+R) were analyzed. Both regimens improved glycemic control at 12 weeks post commencement of new medications. GV, expressed as the mean amplitude of plasma glycemic excursions (MAGE, 5.0 ± 2.6 vs. 2.8 ± 1.6 mmol/L,  
ISSN:2167-8359
2167-8359
DOI:10.7717/peerj.9905